{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T18:56:59Z","timestamp":1781636219763,"version":"3.54.5"},"reference-count":63,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T00:00:00Z","timestamp":1771804800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T00:00:00Z","timestamp":1774828800000},"content-version":"vor","delay-in-days":35,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100013267","name":"Kidscan Children's Cancer Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013267","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Discov Onc"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The c-MET kinase signalling pathway is crucial in cerebellum development and has emerged as a potential therapeutic target for medulloblastoma treatment. Our study confirms that c-MET and its ligand HGF are highly expressed in the SHH medulloblastoma subgroup, with SHH-\u03b1 and SHH-\u03b2 subtypes showing the highest expression levels of both genes, respectively. HGF treatments and siRNA-mediated c-MET knockdown demonstrated the proliferative dependence of SHH MB cells on c-MET signalling. However, time-lapse microscopy revealed heterogeneous behaviours of SHH cell lines following alterations in c-MET levels. Pharmacological inhibition of c-MET signalling showed that tivantinib outperforms other c-MET inhibitors, including crizotinib and foretinib, in killing SHH medulloblastoma cells. Tivantinib induces a prolonged mitotic block followed by apoptotic death in both 2D and 3D cell culture models. Additionally, tivantinib enhances the anti-proliferative activity of vincristine, the standard of care for MB patients, specifically in DAOY cells, where the combination of vincristine and tivantinib synergistically increases the level of PARP cleavage. Moreover, we demonstrated that foretinib and crizotinib induce mitotic slippage in SHH MB cells. The use of navitoclax, a pan-BCL2 inhibitor, initiates the apoptotic program after cells fail mitosis. Taken together, these data suggest that tivantinib is a superior clinical option for SHH MB patients, whereas foretinib or crizotinib should be considered only in combination with BCL2 inhibitors.<\/jats:p>","DOI":"10.1007\/s12672-026-04717-7","type":"journal-article","created":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T08:26:26Z","timestamp":1771835186000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Distinct cMET inhibitors uncover pharmacological heterogeneity in SHH medulloblastoma cell lines"],"prefix":"10.1007","volume":"17","author":[{"given":"Sonia","family":"Morlando","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander W. I.","family":"Cox","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aabha Mahesh","family":"Thite","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruth","family":"Aidoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Wilkinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline H.","family":"Topham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianpiero","family":"Di Leva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,23]]},"reference":[{"key":"4717_CR1","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1093\/neuonc\/noab106","volume":"23","author":"DN Louis","year":"2021","unstructured":"Louis DN, Perry A, Wesseling P, Brat DJ, Cree IA, Figarella-Branger D, et al. The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. Neuro Oncol. 2021;23:1231\u201351. https:\/\/doi.org\/10.1093\/neuonc\/noab106.","journal-title":"Neuro Oncol"},{"key":"4717_CR2","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1038\/s41568-019-0223-8","volume":"20","author":"V Hovestadt","year":"2020","unstructured":"Hovestadt V, Ayrault O, Swartling FJ, Robinson GW, Pfister SM, Northcott PA. Medulloblastomics revisited: biological and clinical insights from thousands of patients. Nat Rev Cancer. 2020;20:42\u201356. https:\/\/doi.org\/10.1038\/s41568-019-0223-8.","journal-title":"Nat Rev Cancer"},{"key":"4717_CR3","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1016\/S2352-4642(20)30246-7","volume":"4","author":"RM Hill","year":"2020","unstructured":"Hill RM, Richardson S, Schwalbe EC, Hicks D, Lindsey JC, Crosier S, et al. Time, pattern, and outcome of medulloblastoma relapse and their association with tumour biology at diagnosis and therapy: a multicentre cohort study. Lancet Child Adolesc Health. 2020;4:865\u201374. https:\/\/doi.org\/10.1016\/S2352-4642(20)30246-7.","journal-title":"Lancet Child Adolesc Health"},{"key":"4717_CR4","doi-asserted-by":"publisher","first-page":"E246","DOI":"10.25011\/cim.v35i5.18697","volume":"35","author":"NF Ajeawung","year":"2012","unstructured":"Ajeawung NF, Wang HY, Gould P, Kamnasaran D. Advances in molecular targets for the treatment of medulloblastomas. Clin Invest Med. 2012;35:E246. https:\/\/doi.org\/10.25011\/cim.v35i5.18697.","journal-title":"Clin Invest Med"},{"key":"4717_CR5","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1038\/s42003-020-01306-4","volume":"3","author":"M Penco-Campillo","year":"2020","unstructured":"Penco-Campillo M, Comoglio Y, Feliz Morel \u00c1J, Hanna R, Durivault J, Leloire M, et al. VEGFC negatively regulates the growth and aggressiveness of medulloblastoma cells. Commun Biol. 2020;3:579. https:\/\/doi.org\/10.1038\/s42003-020-01306-4.","journal-title":"Commun Biol"},{"key":"4717_CR6","doi-asserted-by":"publisher","first-page":"e0141381","DOI":"10.1371\/journal.pone.0141381","volume":"10","author":"WW Zomerman","year":"2015","unstructured":"Zomerman WW, Plasschaert SLA, Diks SH, Lourens H-J, Meeuwsen-de Boer T, Hoving EW, et al. Exogenous HGF Bypasses the Effects of ErbB Inhibition on Tumor Cell Viability in Medulloblastoma Cell Lines. PLoS ONE. 2015;10:e0141381. https:\/\/doi.org\/10.1371\/journal.pone.0141381.","journal-title":"PLoS ONE"},{"key":"4717_CR7","doi-asserted-by":"publisher","first-page":"9355","DOI":"10.1158\/0008-5472.CAN-05-1946","volume":"65","author":"Y Li","year":"2005","unstructured":"Li Y, Lal B, Kwon S, Fan X, Saldanha U, Reznik TE, et al. The Scatter Factor\/Hepatocyte Growth Factor: c-Met Pathway in Human Embryonal Central Nervous System Tumor Malignancy. Cancer Res. 2005;65:9355\u201362. https:\/\/doi.org\/10.1158\/0008-5472.CAN-05-1946.","journal-title":"Cancer Res"},{"key":"4717_CR8","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.ejca.2005.11.023","volume":"42","author":"RJ Gilbertson","year":"2006","unstructured":"Gilbertson RJ, Langdon JA, Hollander A, Hernan R, Hogg TL, Gajjar A, et al. Mutational analysis of PDGFR\u2013RAS\/MAPK pathway activation in childhood medulloblastoma. Eur J Cancer. 2006;42:646\u20139. https:\/\/doi.org\/10.1016\/j.ejca.2005.11.023.","journal-title":"Eur J Cancer"},{"key":"4717_CR9","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1016\/j.ccell.2018.08.004","volume":"34","author":"TC Archer","year":"2018","unstructured":"Archer TC, Ehrenberger T, Mundt F, Gold MP, Krug K, Mah CK, et al. Proteomics, Post-translational Modifications, and Integrative Analyses Reveal Molecular Heterogeneity within Medulloblastoma Subgroups. Cancer Cell. 2018;34:396\u2013e4108. https:\/\/doi.org\/10.1016\/j.ccell.2018.08.004.","journal-title":"Cancer Cell"},{"key":"4717_CR10","doi-asserted-by":"publisher","unstructured":"Forget A, Martignetti L, Puget S, Calzone L, Brabetz S, Picard D, et al. Aberrant ERBB4-SRC Signaling as a Hallmark of Group 4 Medulloblastoma Revealed by Integrative Phosphoproteomic Profiling. Cancer Cell. 2018;34:379\u2013395.e7. https:\/\/doi.org\/10.1016\/j.ccell.2018.08.002.","DOI":"10.1016\/j.ccell.2018.08.002"},{"key":"4717_CR11","doi-asserted-by":"publisher","first-page":"683609","DOI":"10.3389\/fcell.2021.683609","volume":"9","author":"C Desole","year":"2021","unstructured":"Desole C, Gallo S, Vitacolonna A, Montarolo F, Bertolotto A, Vivien D, et al. HGF and MET: from Brain Development to Neurological Disorders. Front Cell Dev Biol. 2021;9:683609. https:\/\/doi.org\/10.3389\/fcell.2021.683609.","journal-title":"Front Cell Dev Biol"},{"key":"4717_CR12","doi-asserted-by":"publisher","unstructured":"Ieraci A, Forni PE, Ponzetto C. Viable hypomorphic signaling mutant of the Met receptor reveals a role for hepatocyte growth factor in postnatal cerebellar development. Proceedings of the National Academy of Sciences. 2002;99:15200\u20135. https:\/\/doi.org\/10.1073\/pnas.222362099","DOI":"10.1073\/pnas.222362099"},{"key":"4717_CR13","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1038\/labinvest.3780280","volume":"81","author":"AB-Y Hui","year":"2001","unstructured":"Hui AB-Y, Lo K-W, Yin X-L, Poon W-S, Ng H-K. Detection of Multiple Gene Amplifications in Glioblastoma Multiforme Using Array-Based Comparative Genomic Hybridization. Lab Invest. 2001;81:717\u201323. https:\/\/doi.org\/10.1038\/labinvest.3780280.","journal-title":"Lab Invest"},{"key":"4717_CR14","doi-asserted-by":"publisher","first-page":"9945","DOI":"10.1158\/0008-5472.CAN-08-2169","volume":"68","author":"PN Kongkham","year":"2008","unstructured":"Kongkham PN, Northcott PA, Ra YS, Nakahara Y, Mainprize TG, Croul SE, et al. An Epigenetic Genome-Wide Screen Identifies SPINT2 as a Novel Tumor Suppressor Gene in Pediatric Medulloblastoma. Cancer Res. 2008;68:9945\u201353. https:\/\/doi.org\/10.1158\/0008-5472.CAN-08-2169.","journal-title":"Cancer Res"},{"key":"4717_CR15","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.1158\/1078-0432.CCR-12-2832","volume":"19","author":"Y Zhang","year":"2013","unstructured":"Zhang Y, Farenholtz KE, Yang Y, Guessous F, diPierro CG, Calvert VS, et al. Hepatocyte Growth Factor Sensitizes Brain Tumors to c-MET Kinase Inhibition. Clin Cancer Res. 2013;19:1433\u201344. https:\/\/doi.org\/10.1158\/1078-0432.CCR-12-2832.","journal-title":"Clin Cancer Res"},{"key":"4717_CR16","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.ccr.2004.05.032","volume":"6","author":"P Michieli","year":"2004","unstructured":"Michieli P, Mazzone M, Basilico C, Cavassa S, Sottile A, Naldini L, et al. Targeting the tumor and its microenvironment by a dual-function decoy Met receptor. Cancer Cell. 2004;6:61\u201373. https:\/\/doi.org\/10.1016\/j.ccr.2004.05.032.","journal-title":"Cancer Cell"},{"key":"4717_CR17","doi-asserted-by":"publisher","first-page":"28","DOI":"10.2174\/1871520611009010028","volume":"10","author":"F Guessous","year":"2010","unstructured":"Guessous F, Zhang Y, diPierro C, Marcinkiewicz L, Sarkaria J, Schiff D, et al. An Orally Bioavailable c-Met Kinase Inhibitor Potently Inhibits Brain Tumor Malignancy and Growth. Anticancer Agents Med Chem. 2010;10:28\u201335. https:\/\/doi.org\/10.2174\/1871520611009010028.","journal-title":"Anticancer Agents Med Chem"},{"key":"4717_CR18","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1158\/0008-5472.CAN-13-3629","volume":"75","author":"CC Faria","year":"2015","unstructured":"Faria CC, Golbourn BJ, Dubuc AM, Remke M, Diaz RJ, Agnihotri S, et al. Foretinib Is Effective Therapy for Metastatic Sonic Hedgehog Medulloblastoma. Cancer Res. 2015;75:134\u201346. https:\/\/doi.org\/10.1158\/0008-5472.CAN-13-3629.","journal-title":"Cancer Res"},{"key":"4717_CR19","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/j.tig.2020.11.001","volume":"37","author":"J Garcia-Lopez","year":"2021","unstructured":"Garcia-Lopez J, Kumar R, Smith KS, Northcott PA. Deconstructing Sonic Hedgehog Medulloblastoma: molecular Subtypes, Drivers, and Beyond. Trends Genet. 2021;37:235\u201350. https:\/\/doi.org\/10.1016\/j.tig.2020.11.001.","journal-title":"Trends Genet"},{"key":"4717_CR20","doi-asserted-by":"publisher","first-page":"7838","DOI":"10.1158\/0008-5472.CAN-08-1899","volume":"68","author":"MJ Binning","year":"2008","unstructured":"Binning MJ, Niazi T, Pedone CA, Lal B, Eberhart CG, Kim KJ, et al. Hepatocyte Growth Factor and Sonic Hedgehog Expression in Cerebellar Neural Progenitor Cells Costimulate Medulloblastoma Initiation and Growth. Cancer Res. 2008;68:7838\u201345. https:\/\/doi.org\/10.1158\/0008-5472.CAN-08-1899.","journal-title":"Cancer Res"},{"key":"4717_CR21","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1016\/j.ccell.2017.05.005","volume":"31","author":"FMG Cavalli","year":"2017","unstructured":"Cavalli FMG, Remke M, Rampasek L, Peacock J, Shih DJH, Luu B, et al. Intertumoral Heterogeneity within Medulloblastoma Subgroups. Cancer Cell. 2017;31:737\u2013e7546. https:\/\/doi.org\/10.1016\/j.ccell.2017.05.005.","journal-title":"Cancer Cell"},{"key":"4717_CR22","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1038\/s41586-019-1434-6","volume":"572","author":"V Hovestadt","year":"2019","unstructured":"Hovestadt V, Smith KS, Bihannic L, Filbin MG, Shaw ML, Baumgartner A, et al. Resolving medulloblastoma cellular architecture by single-cell genomics. Nature. 2019;572:74\u20139. https:\/\/doi.org\/10.1038\/s41586-019-1434-6.","journal-title":"Nature"},{"key":"4717_CR23","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1038\/nrm1261","volume":"4","author":"C Birchmeier","year":"2003","unstructured":"Birchmeier C, Birchmeier W, Gherardi E, Vande Woude GF. Met, metastasis, motility and more. Nat Rev Mol Cell Biol. 2003;4:915\u201325. https:\/\/doi.org\/10.1038\/nrm1261.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"4717_CR24","doi-asserted-by":"publisher","first-page":"4408","DOI":"10.1158\/0008-5472.CAN-06-4443","volume":"67","author":"HY Zou","year":"2007","unstructured":"Zou HY, Li Q, Lee JH, Arango ME, McDonnell SR, Yamazaki S, et al. An Orally Available Small-Molecule Inhibitor of c-Met, PF-2341066, Exhibits Cytoreductive Antitumor Efficacy through Antiproliferative and Antiangiogenic Mechanisms. Cancer Res. 2007;67:4408\u201317. https:\/\/doi.org\/10.1158\/0008-5472.CAN-06-4443.","journal-title":"Cancer Res"},{"key":"4717_CR25","doi-asserted-by":"publisher","unstructured":"Rong S, Segal S, Anver M, Resau JH, Vande Woude GF. Invasiveness and metastasis of NIH 3T3 cells induced by Met-hepatocyte growth factor\/scatter factor autocrine stimulation. Proc Natl Acad Sci. 1994;91:4731\u20135. https:\/\/doi.org\/10.1073\/pnas.91.11.4731.","DOI":"10.1073\/pnas.91.11.4731"},{"key":"4717_CR26","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1038\/nrc3205","volume":"12","author":"E Gherardi","year":"2012","unstructured":"Gherardi E, Birchmeier W, Birchmeier C, Woude G Vande. Targeting MET in cancer: rationale and progress. Nat Rev Cancer. 2012;12:89\u2013103. https:\/\/doi.org\/10.1038\/nrc3205.","journal-title":"Nat Rev Cancer"},{"key":"4717_CR27","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aba7401","author":"R Endersby","year":"2021","unstructured":"Endersby R, Whitehouse J, Pribnow A, Kuchibhotla M, Hii H, Carline B, et al. Small-molecule screen reveals synergy of cell cycle checkpoint kinase inhibitors with DNA-damaging chemotherapies in medulloblastoma. Sci Transl Med. 2021. https:\/\/doi.org\/10.1126\/scitranslmed.aba7401.","journal-title":"Sci Transl Med"},{"key":"4717_CR28","doi-asserted-by":"publisher","first-page":"5176","DOI":"10.18632\/oncotarget.6894","volume":"7","author":"O Sloss","year":"2016","unstructured":"Sloss O, Topham C, Diez M, Taylor S. Mcl-1 dynamics influence mitotic slippage and death in mitosis. Oncotarget. 2016;7:5176\u201392. https:\/\/doi.org\/10.18632\/oncotarget.6894.","journal-title":"Oncotarget"},{"key":"4717_CR29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2174\/1568011023354290","volume":"2","author":"M Jordan","year":"2012","unstructured":"Jordan M. Mechanism of Action of Antitumor Drugs that Interact with Microtubules and Tubulin. Curr Med Chemistry-Anti-Cancer Agents. 2012;2:1\u201317. https:\/\/doi.org\/10.2174\/1568011023354290.","journal-title":"Curr Med Chemistry-Anti-Cancer Agents"},{"key":"4717_CR30","doi-asserted-by":"publisher","first-page":"186","DOI":"10.3390\/cancers12010186","volume":"12","author":"Z-X Wu","year":"2020","unstructured":"Wu Z-X, Yang Y, Teng Q-X, Wang J-Q, Lei Z-N, Wang J-Q, et al. Tivantinib, A c-Met Inhibitor in Clinical Trials, Is Susceptible to ABCG2-Mediated Drug Resistance. Cancers (Basel). 2020;12:186. https:\/\/doi.org\/10.3390\/cancers12010186.","journal-title":"Cancers (Basel)"},{"key":"4717_CR31","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1158\/0008-5472.CAN-09-1947","volume":"70","author":"T-C Chou","year":"2010","unstructured":"Chou T-C. Drug Combination Studies and Their Synergy Quantification Using the Chou-Talalay Method. Cancer Res. 2010;70:440\u20136. https:\/\/doi.org\/10.1158\/0008-5472.CAN-09-1947.","journal-title":"Cancer Res"},{"key":"4717_CR32","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1080\/15384101.2018.1559557","volume":"18","author":"D Sinha","year":"2019","unstructured":"Sinha D, Duijf PHG, Khanna KK. Mitotic slippage: an old tale with a new twist. Cell Cycle. 2019;18:7\u201315. https:\/\/doi.org\/10.1080\/15384101.2018.1559557.","journal-title":"Cell Cycle"},{"key":"4717_CR33","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.1016\/j.cub.2006.04.043","volume":"16","author":"DA Brito","year":"2006","unstructured":"Brito DA, Rieder CL. Mitotic Checkpoint Slippage in Humans Occurs via Cyclin B Destruction in the Presence of an Active Checkpoint. Curr Biol. 2006;16:1194\u2013200. https:\/\/doi.org\/10.1016\/j.cub.2006.04.043.","journal-title":"Curr Biol"},{"key":"4717_CR34","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1016\/j.ceb.2013.07.003","volume":"25","author":"CH Topham","year":"2013","unstructured":"Topham CH, Taylor SS. Mitosis and apoptosis: How is the balance set? Curr Opin Cell Biol. 2013;25:780\u20135. https:\/\/doi.org\/10.1016\/j.ceb.2013.07.003.","journal-title":"Curr Opin Cell Biol"},{"key":"4717_CR35","doi-asserted-by":"publisher","first-page":"5374","DOI":"10.1038\/s41598-021-84082-3","volume":"11","author":"M Buzzetti","year":"2021","unstructured":"Buzzetti M, Morlando S, Solomos D, Mehmood A, Cox AWI, Chiesa M, et al. Pre-therapeutic efficacy of the CDK inhibitor dinaciclib in medulloblastoma cells. Sci Rep. 2021;11:5374. https:\/\/doi.org\/10.1038\/s41598-021-84082-3.","journal-title":"Sci Rep"},{"key":"4717_CR36","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.jbiotec.2016.07.028","volume":"236","author":"DP Ivanov","year":"2016","unstructured":"Ivanov DP, Coyle B, Walker DA, Grabowska AM. In vitro models of medulloblastoma: choosing the right tool for the job. J Biotechnol. 2016;236:10\u201325. https:\/\/doi.org\/10.1016\/j.jbiotec.2016.07.028.","journal-title":"J Biotechnol"},{"key":"4717_CR37","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1002\/(SICI)1097-4547(20000215)59:4<489::AID-JNR3>3.0.CO;2-9","volume":"59","author":"L Zhang","year":"2000","unstructured":"Zhang L, Himi T, Morita I, Murota S. Hepatocyte growth factor protects cultured rat cerebellar granule neurons from apoptosis via the phosphatidylinositol-3 kinase\/Akt pathway. J Neurosci Res. 2000;59:489\u201396.","journal-title":"J Neurosci Res"},{"key":"4717_CR38","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1016\/S0960-9822(99)80195-X","volume":"9","author":"VA Wallace","year":"1999","unstructured":"Wallace VA. Purkinje-cell-derived Sonic hedgehog regulates granule neuron precursor cell proliferation in the developing mouse cerebellum. Curr Biol. 1999;9:445\u20138. https:\/\/doi.org\/10.1016\/S0960-9822(99)80195-X.","journal-title":"Curr Biol"},{"key":"4717_CR39","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/S0896-6273(00)80682-0","volume":"22","author":"RJ Wechsler-Reya","year":"1999","unstructured":"Wechsler-Reya RJ, Scott MP. Control of Neuronal Precursor Proliferation in the Cerebellum by Sonic Hedgehog. Neuron. 1999;22:103\u201314. https:\/\/doi.org\/10.1016\/S0896-6273(00)80682-0.","journal-title":"Neuron"},{"key":"4717_CR40","doi-asserted-by":"publisher","unstructured":"Dahmane N, Altaba AR. i. Sonic hedgehog regulates the growth and patterning of the cerebellum. Development 1999;126:3089\u2013100. https:\/\/doi.org\/10.1242\/dev.126.14.3089.","DOI":"10.1242\/dev.126.14.3089"},{"key":"4717_CR41","doi-asserted-by":"publisher","first-page":"46","DOI":"10.3390\/biomedicines3010046","volume":"3","author":"G Viticchi\u00e8","year":"2015","unstructured":"Viticchi\u00e8 G, Muller P. c-Met and Other Cell Surface Molecules: interaction, Activation and Functional Consequences. Biomedicines. 2015;3:46\u201370. https:\/\/doi.org\/10.3390\/biomedicines3010046.","journal-title":"Biomedicines"},{"key":"4717_CR42","doi-asserted-by":"publisher","first-page":"1536","DOI":"10.1002\/ijc.28169","volume":"133","author":"A Varkaris","year":"2013","unstructured":"Varkaris A, Gaur S, Parikh NU, Song JH, Dayyani F, Jin J, et al. Ligand-independent activation of MET through IGF\u20101\/IGF\u20101R signaling. Int J Cancer. 2013;133:1536\u201346. https:\/\/doi.org\/10.1002\/ijc.28169.","journal-title":"Int J Cancer"},{"key":"4717_CR43","doi-asserted-by":"publisher","first-page":"1400","DOI":"10.1200\/JCO.2010.30.2810","volume":"29","author":"DW Ellison","year":"2011","unstructured":"Ellison DW, Kocak M, Dalton J, Megahed H, Lusher ME, Ryan SL, et al. Definition of Disease-Risk Stratification Groups in Childhood Medulloblastoma Using Combined Clinical, Pathologic, and Molecular Variables. J Clin Oncol. 2011;29:1400\u20137. https:\/\/doi.org\/10.1200\/JCO.2010.30.2810.","journal-title":"J Clin Oncol"},{"key":"4717_CR44","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1016\/S1470-2045(17)30243-7","volume":"18","author":"EC Schwalbe","year":"2017","unstructured":"Schwalbe EC, Lindsey JC, Nakjang S, Crosier S, Smith AJ, Hicks D, et al. Novel molecular subgroups for clinical classification and outcome prediction in childhood medulloblastoma: a cohort study. Lancet Oncol. 2017;18:958\u201371. https:\/\/doi.org\/10.1016\/S1470-2045(17)30243-7.","journal-title":"Lancet Oncol"},{"key":"4717_CR45","doi-asserted-by":"publisher","first-page":"2927","DOI":"10.1200\/JCO.2012.48.5052","volume":"31","author":"N Zhukova","year":"2013","unstructured":"Zhukova N, Ramaswamy V, Remke M, Pfaff E, Shih DJH, Martin DC, et al. Subgroup-Specific Prognostic Implications of TP53 Mutation in Medulloblastoma. J Clin Oncol. 2013;31:2927\u201335. https:\/\/doi.org\/10.1200\/JCO.2012.48.5052.","journal-title":"J Clin Oncol"},{"key":"4717_CR46","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1007\/s00401-011-0846-7","volume":"122","author":"PA Northcott","year":"2011","unstructured":"Northcott PA, Hielscher T, Dubuc A, Mack S, Shih D, Remke M, et al. Pediatric and adult sonic hedgehog medulloblastomas are clinically and molecularly distinct. Acta Neuropathol. 2011;122:231\u201340. https:\/\/doi.org\/10.1007\/s00401-011-0846-7.","journal-title":"Acta Neuropathol"},{"key":"4717_CR47","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1021\/cb400660a","volume":"9","author":"LL Remsing Rix","year":"2014","unstructured":"Remsing Rix LL, Kuenzi BM, Luo Y, Remily-Wood E, Kinose F, Wright G, et al. GSK3 Alpha and Beta Are New Functionally Relevant Targets of Tivantinib in Lung Cancer Cells. ACS Chem Biol. 2014;9:353\u20138. https:\/\/doi.org\/10.1021\/cb400660a.","journal-title":"ACS Chem Biol"},{"key":"4717_CR48","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1186\/s13046-015-0238-2","volume":"34","author":"Q Xiang","year":"2015","unstructured":"Xiang Q, Zhen Z, Deng DY, Wang J, Chen Y, Li J, et al. Tivantinib induces G2\/M arrest and apoptosis by disrupting tubulin polymerization in hepatocellular carcinoma. J Experimental Clin Cancer Res. 2015;34:118. https:\/\/doi.org\/10.1186\/s13046-015-0238-2.","journal-title":"J Experimental Clin Cancer Res"},{"key":"4717_CR49","doi-asserted-by":"publisher","first-page":"1633","DOI":"10.1007\/s10637-020-00940-3","volume":"38","author":"BJ Kim","year":"2020","unstructured":"Kim BJ, Kim YJ, Sohn S-H, Kim B, Sul HJ, Kim HS, et al. Tivantinib inhibits the VEGF signaling pathway and induces apoptosis in gastric cancer cells with c-MET or VEGFA amplification. Invest New Drugs. 2020;38:1633\u201340. https:\/\/doi.org\/10.1007\/s10637-020-00940-3.","journal-title":"Invest New Drugs"},{"key":"4717_CR50","doi-asserted-by":"publisher","first-page":"106062","DOI":"10.1016\/j.isci.2023.106062","volume":"26","author":"Y Huang","year":"2023","unstructured":"Huang Y, Guo Y, Zhou Y, Huang Q, Ru Y, Luo Y, et al. Tivantinib alleviates inflammatory diseases by directly targeting NLRP3. IScience. 2023;26:106062. https:\/\/doi.org\/10.1016\/j.isci.2023.106062.","journal-title":"IScience"},{"key":"4717_CR51","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1158\/1535-7163.MCT-13-0187","volume":"13","author":"Y Zhou","year":"2014","unstructured":"Zhou Y, Zhao C, Gery S, Braunstein GD, Okamoto R, Alvarez R, et al. Off-Target Effects of c-MET Inhibitors on Thyroid Cancer Cells. Mol Cancer Ther. 2014;13:134\u201343. https:\/\/doi.org\/10.1158\/1535-7163.MCT-13-0187.","journal-title":"Mol Cancer Ther"},{"key":"4717_CR52","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1186\/s12885-024-12780-y","volume":"24","author":"F Lu","year":"2024","unstructured":"Lu F, Zhao K, Ye M, Xing G, Liu B, Li X, et al. Efficacy and safety of second-line therapies for advanced hepatocellular carcinoma: a network meta-analysis of randomized controlled trials. BMC Cancer. 2024;24:1023. https:\/\/doi.org\/10.1186\/s12885-024-12780-y.","journal-title":"BMC Cancer"},{"key":"4717_CR53","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.731527","author":"S Zhao","year":"2021","unstructured":"Zhao S, Wu W, Jiang H, Ma L, Pan C, Jin C, et al. Selective Inhibitor of the c-Met Receptor Tyrosine Kinase in Advanced Hepatocellular Carcinoma: No Beneficial Effect With the Use of Tivantinib? Front Immunol. 2021. https:\/\/doi.org\/10.3389\/fimmu.2021.731527.","journal-title":"Front Immunol"},{"key":"4717_CR54","doi-asserted-by":"publisher","first-page":"3759","DOI":"10.1111\/cas.14582","volume":"111","author":"M Kudo","year":"2020","unstructured":"Kudo M, Morimoto M, Moriguchi M, Izumi N, Takayama T, Yoshiji H, et al. A randomized, double-blind, placebo\u2010controlled, phase 3 study of tivantinib in Japanese patients with MET\u2010high hepatocellular carcinoma. Cancer Sci. 2020;111:3759\u201369. https:\/\/doi.org\/10.1111\/cas.14582.","journal-title":"Cancer Sci"},{"key":"4717_CR55","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1016\/S1470-2045(18)30146-3","volume":"19","author":"L Rimassa","year":"2018","unstructured":"Rimassa L, Assenat E, Peck-Radosavljevic M, Pracht M, Zagonel V, Mathurin P, et al. Tivantinib for second-line treatment of MET-high, advanced hepatocellular carcinoma (METIV-HCC): a final analysis of a phase 3, randomised, placebo-controlled study. Lancet Oncol. 2018;19:682\u201393. https:\/\/doi.org\/10.1016\/S1470-2045(18)30146-3.","journal-title":"Lancet Oncol"},{"key":"4717_CR56","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.26565","author":"JI Geller","year":"2017","unstructured":"Geller JI, Perentesis JP, Liu X, Minard CG, Kudgus RA, Reid JM, et al. A phase 1 study of the c-Met inhibitor, tivantinib (ARQ197) in children with relapsed or refractory solid tumors: a Children\u2019s Oncology Group study phase 1 and pilot consortium trial (ADVL1111). Pediatr Blood Cancer. 2017. https:\/\/doi.org\/10.1002\/pbc.26565.","journal-title":"Pediatr Blood Cancer"},{"key":"4717_CR57","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.semcancer.2018.07.004","volume":"53","author":"J Liu","year":"2018","unstructured":"Liu J. The dualistic origin of human tumors. Semin Cancer Biol. 2018;53:1\u201316. https:\/\/doi.org\/10.1016\/j.semcancer.2018.07.004.","journal-title":"Semin Cancer Biol"},{"key":"4717_CR58","doi-asserted-by":"publisher","first-page":"783","DOI":"10.4161\/cc.23720","volume":"12","author":"P Duesberg","year":"2013","unstructured":"Duesberg P, McCormack A. Immortality of cancers. Cell Cycle. 2013;12:783\u2013802. https:\/\/doi.org\/10.4161\/cc.23720.","journal-title":"Cell Cycle"},{"key":"4717_CR59","doi-asserted-by":"publisher","first-page":"83","DOI":"10.3390\/genes10020083","volume":"10","author":"K Salmina","year":"2019","unstructured":"Salmina K, Huna A, Kalejs M, Pjanova D, Scherthan H, Cragg MS, et al. The Cancer Aneuploidy Paradox: in the Light of Evolution. Genes (Basel). 2019;10:83. https:\/\/doi.org\/10.3390\/genes10020083.","journal-title":"Genes (Basel)"},{"key":"4717_CR60","doi-asserted-by":"publisher","DOI":"10.1098\/rsob.160134","author":"A Bennett","year":"2016","unstructured":"Bennett A, Sloss O, Topham C, Nelson L, Tighe A, Taylor SS. Inhibition of Bcl-xL sensitizes cells to mitotic blockers, but not mitotic drivers. Open Biol. 2016. https:\/\/doi.org\/10.1098\/rsob.160134.","journal-title":"Open Biol"},{"key":"4717_CR61","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1097\/00005072-198509000-00003","volume":"44","author":"PF Jacobsen","year":"1985","unstructured":"Jacobsen PF, Jenkin DJ, Papadimitriou JM. Establishment of a Human Medulloblastoma Cell Line and Its Heterotransplantation into Nude Mice. J Neuropathol Exp Neurol. 1985;44:472\u201385. https:\/\/doi.org\/10.1097\/00005072-198509000-00003.","journal-title":"J Neuropathol Exp Neurol"},{"key":"4717_CR62","first-page":"695","volume":"41","author":"M Yamada","year":"1989","unstructured":"Yamada M, Shimizu K, Tamura K, Okamoto Y, Matsui Y, Moriuchi S, et al. Establishment and biological characterization of human medulloblastoma cell lines. No Shinkei. 1989;41:695\u2013702.","journal-title":"No Shinkei"},{"key":"4717_CR63","doi-asserted-by":"publisher","first-page":"D1407","DOI":"10.1093\/nar\/gkad753","volume":"52","author":"Y Deng","year":"2024","unstructured":"Deng Y, Chen P, Xiao J, Li M, Shen J, Qin S, et al. SCAR: Single-cell and Spatially-resolved Cancer Resources. Nucleic Acids Res. 2024;52:D1407\u201317. https:\/\/doi.org\/10.1093\/nar\/gkad753.","journal-title":"Nucleic Acids Res"}],"container-title":["Discover Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12672-026-04717-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-026-04717-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-026-04717-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T18:41:11Z","timestamp":1781635271000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12672-026-04717-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,23]]},"references-count":63,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4717"],"URL":"https:\/\/doi.org\/10.1007\/s12672-026-04717-7","relation":{},"ISSN":["2730-6011"],"issn-type":[{"value":"2730-6011","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,23]]},"assertion":[{"value":"8 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Neither Institutional Review Board (IRB) approval nor explicit consent was required, given that the R2 database provides publicly accessible anonymized data.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Gianpiero Di Leva declares he is an Editorial Board Member of Discover Oncology and confirms that he was not involved in the handling or decision-making of the submission.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"506"}}